Purpose: We sought to investigate the prevalence and variables associated with early oncologic failure. Materials and Methods: We retrospectively reviewed the IRCC (International Radical Cystectomy Consortium) database of patients who underwent robotassisted radical cystectomy since 2003. The final cohort comprised a total of 1,894 patients from 23 institutions in 11 countries. Early oncologic failure was defined as any disease relapse within 3 months of robot-assisted radical cystectomy. All institutions were surveyed for the pneumoperitoneum pressure used, breach of oncologic surgical principles, and techniques of specimen and lymph node removal. A multivariate model was fit to evaluate predictors of early oncologic failure. The Kaplan-Meier method was applied to depict disease specific and overall survival, and Cox proportional regression analysis was used to evaluate predictors of disease specific and overall survival. Results: A total of 305 patients (22%) experienced disease relapse, which was distant in 220 (16%), local recurrence in 154 (11%), peritoneal carcinomatosis in 17 (1%) and port site recurrence in 5 (0.4%). Early oncologic failure developed in 71 patients (5%) at a total of 10 institutions. The incidence of early oncologic failure decreased from 10% in 2006 to 6% in 2015. On multivariate analysis the Accepted for publication December 10, 2016. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
RADICAL cystectomy with pelvic lymph node dissection represents the gold standard for the management of nonmetastatic muscle invasive bladder cancer and refractory nonmuscle invasive disease. More interest has been spurred in RARC aiming to improve perioperative outcomes, including blood loss, transfusion rates, hospital stay and recovery, without compromising oncologic efficacy.
1,2 Consequently, the past decade has witnessed a paramount shift in the utilization of RARC from less than 1% in 2004 to 13% in 2010. 2 Nevertheless, much of the criticism to RARC has been attributable to the lack of long-term oncologic outcomes and patient selection bias. There have also been concerns regarding adherence to key oncologic tenets and the induction of local pelvic, peritoneal and port site recurrences during minimally invasive approaches to RC. 3 Despite aggressive management more than half of the patients with muscle invasive bladder cancer experience local or systemic relapse, usually within the first 2 years after surgery, with a deleterious impact on survival. 4 Disease extent at the time of surgery or a breach of oncologic surgical principles may contribute to disease relapse. Known predictors of disease relapse include perioperative chemotherapy, extent of pelvic lymph node dissection, pathological T stage, lymph node status and positive soft tissue surgical margins at cystectomy. 5 In this study we queried the multinational, prospectively maintained, quality assurance IRCC database to investigate the prevalence of EOF after RARC. EOF was defined as any disease relapse within the first 3 months following surgery in patients who underwent RARC during more than a decade. We further sought to investigate possible factors contributing to EOF. To our knowledge this is the first study to address possible early recurrences related to technical faults after RARC.
METHODS
We retrospectively reviewed the records of 2,460 patients at a total of 29 institutions included in the IRCC database (I-97906). The 566 patients from institutions that failed to provide updated data were excluded from study. The final cohort comprised 1,894 patients from a total of 23 institutions across 11 countries who were treated with RARC since 2003 ( fig. 1 ).
Data were reviewed for patient age, gender, body mass index, ASAÒ score, preoperative characteristics (neoadjuvant chemotherapy, prior abdominal surgery and clinical staging), operative variables (diversion type and technique, operative time, estimated blood loss and blood transfusion), perioperative outcomes (complications, readmissions, and hospital and intensive care unit stay) and pathological outcomes (staging, lymph node yield and soft tissue surgical margins). The techniques of RARC and urinary diversion, and followup differed among institutions.
Disease relapse was defined in terms of recurrence type (local, distant, port site or peritoneal carcinomatosis), anatomical site and timing since cystectomy. The latter included EOF, defined as any disease relapse within 90 days after RARC, vs later or no recurrence. We chose 90 days as a cutoff for EOF so that these recurrences were most likely related to the surgical technique rather than to disease severity. All patients had at least 3 months of followup. Institutions with patients who had EOF were surveyed for the use of pneumoperitoneum pressure, breach of oncologic principles during RARC, including urine spillage during the procedure, and the techniques of specimen and lymph node removal.
Descriptive statistics were used to summarize the data. Univariable associations were statistically assessed using the Pearson chi-square or Fisher exact test. Univariate and multivariate (stepwise variable selection) logistic regression models were fit to evaluate preoperative, operative and postoperative predictors of EOF following RARC. The Kaplan-Meier method was used to depict DSS and OS for patients with EOF vs those who did not show EOF. All tests were 2-sided with statistical significance considered at p <0.05. All statistical analyses were performed with SASÒ, version 9.4.
RESULTS
Of the 1,894 patients included in study 30 died of noncancer related causes and 484 had incomplete recurrence data available. A total of 1,380 patients with complete data were included in the final analysis ( fig. 1) .
At a mean followup of 24 months 305 patients (22%) experienced disease relapse, 220 (16%) had distant recurrence, 154 (11%) had local recurrence, 17 (1%) had peritoneal carcinomatosis and 5 (0.4%) had port site recurrence. EOF developed in 71 patients (5%) at a total of 10 institutions and the incidence of EOF decreased from 10% in 2006 to 6% in 2015 ( fig. 2 ). Compared with patients in whom later or no recurrence developed, those who experienced EOF showed significantly higher estimated blood loss, received blood transfusion and adjuvant chemotherapy more frequently, and demonstrated a higher complication rate. Compared to patients with recurrence at greater than 3 months and those without any recurrence, patients with EOF had a higher prevalence of pT3 (75% vs 68% and 31%) and positive nodal disease (42% vs 36% and 15%, respectively, both p <0.0001). They had a higher rate of positive soft tissue surgical margins compared to patients who did not have any recurrence (13% vs 6%, p <0.001, table 1). Eight patients experienced EOF despite having organ confined disease (less than pT3 and N0). In 3 of these cases a breach of oncologic surgical principles was noted.
Overall, the pelvis was the most common site of local recurrence at 51%. The lung was the most common site of distant recurrence at 24%, followed by bone metastasis at 21% and extrapelvic lymph nodes at 20%. Compared to patients in whom later recurrence developed, those with EOF experienced more pelvic recurrences (37% vs 22%, p ¼ 0.02), extrapelvic lymph node metastases (23% vs 12%, p ¼ 0.03) and bone metastases (24% vs 12%, p ¼ 0.03, table 2).
We surveyed the 10 institutions that had patients with EOF. At 4 institutions operations were done using a higher pneumoperitoneum pressure of 14 mm Hg or greater, while at the remainder 12 mm Hg or less was used. Of patients in whom EOF developed 4 at a total of 2 institutions had possible disseminated disease upon the preoperative metastatic workup. A breach of oncologic principles occurred in 6 patients ( 
DISCUSSION
Despite aggressive management disease relapses after RC in half of the patients, which significantly reduces survival. To our knowledge the pathogenesis of recurrence following RC is yet to be determined but it is probably multifactorial. Tumor aggressiveness, occult metastatic disease at surgery, an inhibited host immune response, laparoscopy related factors such as gas insufflation and desufflation, or breaching of oncologic surgical principles, including vigorous surgical manipulation, specimen morcellation, entry into the bladder and the retrieval method, have been investigated. 6e8 To our knowledge the contribution of CO 2 pneumoperitoneum deployed in minimally invasive surgery remains unknown. Prior animal studies suggested that CO 2 pneumoperitoneum may inhibit the peritoneal immune response against malignant urothelial cells and may contribute to recurrence in the pelvis and at port sites. 9 We identified and characterized patients in whom EOF developed after RARC. Of our patients 5% experienced EOF, including 63 (89%) who had advanced disease (pT3 or greater with or without positive nodal disease). Oncologic principles were breached in 6 patients (8%), including 3 with organ confined disease (less than pT3/N0). For any RC that is performed, whether open or RARC, tumor stage, nodal involvement, lymphovascular invasion and positive soft tissue surgical margins are the most powerful predictors of tumor recurrence. 1, 10 On multivariable analysis EOF was at least twice as likely to develop in patients with extravesical or nodal disease.
During RC tumor spillage may occur in cases of extravesical disease or extensive nodal involvement, or due to technical error, which may risk seeding the peritoneal cavity with UCC. The potential seeding of tumor cells as a source of local recurrences is a concern during open and minimally invasive RC.
While much attention has been given to reporting negative soft tissue surgical margins, measures to prevent urine leakage from the urethra or the ureters should be routine. 11 A survey of 162 members of SUO (Society of Urologic Oncology) revealed that 71% used urethral catheterization, 44% clamped the urethra and 22% ligated or clipped the urethra at RC to prevent urine spillage. 12 The Roswell Park Cancer Institute group initiated a novel approach to objectively evaluate the presence of cancer cells and their gene related products in the pelvis and pneumoperitoneum during RARC. 13 UCC, presumably from tumor spillage during transurethral resection of bladder tumor or after open RC, or from circulating tumor cells, has been reported in abdominal wounds and at suprapubic tube sites, in the pelvic cavity in the resection bed and on the psoas muscle. The use of intravesical instillation of chemotherapy after transurethral resection of bladder tumor to prevent tumor seeding and decrease recurrence has inspired some surgeons to use sterile water to induce hypotonic lysis of any remaining UCC despite unproven efficacy. 17 This raises questions about the possible role of intraperitoneal chemotherapy, similar to those regarding ovarian, gastric and colorectal malignancies. 18, 19 The use of prophylactic radiation or systemic chemotherapy in the setting of UCC spillage remains unclear with significant potential morbidity.
It is worth mentioning that the incidence of EOF decreased with time from 10% in 2006 to 6% in 2015. If these recurrences are surgery related, this trend might be explained by the evolution of the technique of RARC, the learning curve, experience with the procedure and comfort with the robot-assisted platform for surgery. 20 Blood transfusion and poor renal function have been proposed to induce recurrence by affecting immunity and DNA repair. 21 Although patients who had any recurrence received blood transfusion more frequently, this did not reach statistical significance on multivariable analysis. Patients who received a neobladder showed better OS (HR 0.49). A possible explanation is patient selection because patients who receive a neobladder generally have better health and fewer comorbidities. This further explains why the type of diversion affected OS and not DSS in our series. Patients in whom postoperative complications developed were approximately 3 times more likely to have EOF. Complications, especially intraoperatively or early in the postoperative period, may be a result of suboptimal surgical performance, which impacts cancer control and patient survival. 22 To our knowledge no study has demonstrated early oncologic failures but time to oncologic failure has been shown to be a significant predictor of OS after open RC. 4 In a cohort of patients with favorable pathology (pT2 N0 R0 or less) in the ESUT (European Association of Urology Section of UroTechnology) cohort a 9% rate of early unexpected relapses was noted. 23 Similar to our study, disease stage rather than technical factors was the main reason for early failure. However, early failure was defined as disease recurrence within 24 months after surgery. 23 Since most recurrences after RC develop within the first 2 years after surgery, a period of 24 months would make it harder to differentiate recurrences that developed due to tumor biology from those that may have developed due to a breach of oncologic surgical principles. For this reason we defined EOF as any disease relapse within the first 3 months after RARC.
Patients with EOF demonstrated worse DSS and OS compared to patients who experienced later and no recurrence (log rank p <0.0001). Early failure may be a result of unrecognized metastatic disease before surgery or tumor spillage during the procedure. Current imaging techniques lack adequate sensitivity and specificity, especially for low volume metastatic disease. Moreover, it has been shown that in patients with presumably organ confined disease, micrometastatic disease was detected using reverse transcriptase-polymerase chain reaction studies in up to a third of those with histologically negative lymph nodes. 24, 25 Similarly, patients with colorectal, ovarian and urothelial cancers who have local relapse, port site seeding and early metastasis after minimally invasive surgery were previously reported. 20, 26 It remains difficult to determine whether such recurrences develop due to the primary tumor stage or as a result of the surgical procedure. The use of quality scoring can objectively assess and quantify surgical performance, and assess the surgical factors that may contribute to EOF. 22 Interestingly, pneumoperitoneum pressure was not associated with EOF. Prior reports suggested that high and/or pulsatile pneumoperitoneum, especially in lengthy procedures, may enhance the migration of tumor cells from the venous plexus of the bladder (of which the pedicles are squeezed throughout the procedure) and contribute to early tumor recurrence. 6, 27, 28 Identifying patients at higher risk for EOF will provide valuable information for technique modification, preventive measures, patient counseling, risk stratification and prognostication.
Despite the emerging role of RARC as a viable alternative to the traditional open approach, criticisms regarding the RARC literature include the lack of long-term survival data and the inherent patient selection bias, in addition to longer operative time and the associated cost. In our cohort patients with EOF experienced more extrapelvic lymph node metastases than later recurrences (23% vs 12%, p ¼ 0.03).
Nguyen et al suggested that recurrence patterns may differ between open radical cystectomy and RARC. 29 They reported a higher incidence of extrapelvic lymph node metastasis and peritoneal carcinomatosis with RARC. Less thorough lymph node dissection with RARC and possible peritoneal dissemination of malignant urothelial cells with pneumoperitoneum have been considered responsible for these findings. 30 However, the lymph node 
CONCLUSIONS
The incidence of EOF following RARC is low and has decreased with time. Disease related factors rather than technical or laparoscopy related factors have a major role in the development of EOF after RARC.
